{
  "drug_id": "D4BE4598792",
  "canonical_name": "apolipoprotein a-i human apoa-i",
  "total_pmids": 80,
  "evidence_count": {
    "benefit": 12,
    "harm": 6,
    "neutral": 0,
    "unknown": 2
  },
  "evidence_blocks": [
    {
      "pmid": "31567014",
      "title": "Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Despite robust cholesterol lowering, cardiovascular disease risk remains increased in patients with diabetes mellitus. Consistent with this, diabetes mellitus impairs atherosclerosis regression after ",
      "confidence": "medium"
    },
    {
      "pmid": "18287885",
      "title": "Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "An increased plasma level of the major high-density lipoprotein (HDL) component, apolipoprotein A-I (apoA-I) is the aim of several therapeutic strategies for combating atherosclerotic disease. HDL the",
      "confidence": "medium"
    },
    {
      "pmid": "28069582",
      "title": "Human apolipoprotein A-I exerts a prophylactic effect on high-fat diet-induced atherosclerosis via inflammation inhibition in a rabbit model.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Apolipoprotein A-I (apoA-I) is the major functional protein fraction of high-density lipoprotein. The prophylactic effect and mechanism of human apoA-I on atherosclerosis (AS) were investigated in a h",
      "confidence": "medium"
    },
    {
      "pmid": "25030535",
      "title": "Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "High-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (apoA-I) levels are inversely associated with adverse cardiovascular outcomes. Associations between these HDL-C-related measurements",
      "confidence": "medium"
    },
    {
      "pmid": "28939717",
      "title": "Apolipoprotein A-I Modulates Atherosclerosis Through Lymphatic Vessel-Dependent Mechanisms in Mice.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Subcutaneously injected lipid-free apoA-I (apolipoprotein A-I) reduces accumulation of lipid and immune cells within the aortic root of hypercholesterolemic mice without increasing high-density lipopr",
      "confidence": "medium"
    },
    {
      "pmid": "25170076",
      "title": "Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Autoantibodies to apolipoprotein A-I (anti-apoA-I IgG) have been shown to be both markers and mediators of cardiovascular disease, promoting atherogenesis and unstable atherosclerotic plaque. Previous",
      "confidence": "medium"
    },
    {
      "pmid": "23072735",
      "title": "Identification of sites in apolipoprotein A-I susceptible to chymase and carboxypeptidase A digestion.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "MCs (mast cells) adversely affect atherosclerosis by promoting the progression of lesions and plaque destabilization. MC chymase cleaves apoA-I (apolipoprotein A-I), the main protein component of HDL ",
      "confidence": "medium"
    },
    {
      "pmid": "26363436",
      "title": "Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Mutations in human apolipoprotein A-I (apoA-I) are associated with low high-density lipoprotein (HDL) cholesterol levels and pathological conditions such as premature atherosclerosis and amyloidosis. ",
      "confidence": "medium"
    },
    {
      "pmid": "40263360",
      "title": "Apolipoprotein-A1 transports and regulates MMP2 in the blood.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Synthesized in the liver and intestines, apolipoprotein A1 (APOA1) transports cholesterol in high density lipoproteins from atherosclerotic lesions to the liver, protecting against atherosclerotic pla",
      "confidence": "medium"
    },
    {
      "pmid": "17430166",
      "title": "Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "LDL-lowering therapies, predominantly involving statins, have been shown to significantly reduce cardiovascular events in asymptomatic subjects as well as in subjects with clinically established ather",
      "confidence": "medium"
    },
    {
      "pmid": "35120132",
      "title": "Oxidant resistant human apolipoprotein A-I functions similarly to the unmodified human isoform in delaying atherosclerosis progression and promoting atherosclerosis regression in hyperlipidemic mice.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Transgenic overexpression of apolipoprotein A-I (apoA1) has been shown to delay atherosclerosis lesion progression and promote lesion regression in mouse models; however, apoA1 is subject to oxidation",
      "confidence": "medium"
    },
    {
      "pmid": "37913855",
      "title": "Interactions of variants of human apolipoprotein A-I with biopolymeric model matrices. Effect of collagen and heparin.",
      "direction": "unknown",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "The extracellular matrix (ECM) is a complex tridimensional scaffold that actively participates in physiological and pathological events. The objective of this study was to test whether structural prot",
      "confidence": "medium"
    },
    {
      "pmid": "27630170",
      "title": "Human macrophage cathepsin B-mediated C-terminal cleavage of apolipoprotein A-I at Ser228 severely impairs antiatherogenic capacity.",
      "direction": "unknown",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Apolipoprotein A-I (apoA-I) is the major component of HDL and central to the ability of HDL to stimulate ATP-binding cassette transporter A1 (ABCA1)-dependent, antiatherogenic export of cholesterol fr",
      "confidence": "medium"
    },
    {
      "pmid": "16285990",
      "title": "Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "No evidence of premature vascular disease is found in apolipoprotein A-I(Milano) (apoA-I(M)) human carriers, despite very low high density lipoprotein (HDL) cholesterol levels. Whether apoA-I(M) may i",
      "confidence": "medium"
    },
    {
      "pmid": "22986928",
      "title": "Characterization of a human apolipoprotein a-I construct expressed in a bacterial system.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Apolipoprotein A-I (apoA-I) is the major protein component of high density lipoproteins. This protein has key functions in lipoprotein metabolism and its plasma concentration is inversely correlated w",
      "confidence": "medium"
    },
    {
      "pmid": "40371638",
      "title": "Asparagine endopeptidase cleaves apolipoprotein A1 and accelerates pathogenesis of atherosclerosis.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Atherosclerosis is a slowly progressing inflammatory disease characterized with cholesterol disorder and intimal plaques. Asparagine endopeptidase (AEP) is an endolysosomal protease that is activated ",
      "confidence": "medium"
    },
    {
      "pmid": "26681753",
      "title": "Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Apolipoprotein A-I (apoA-I) has been shown to possess several atheroprotective functions, including inhibition of inflammation. Protease-secreting activated mast cells reside in human atherosclerotic ",
      "confidence": "medium"
    },
    {
      "pmid": "31904503",
      "title": "Fibrillar conformation of an apolipoprotein A-I variant involved in amyloidosis and atherosclerosis.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Different protein conformations may be involved in the development of clinical manifestations associated with human amyloidosis. Although a fibrillar conformation is usually the signature of damage in",
      "confidence": "medium"
    },
    {
      "pmid": "29437574",
      "title": "CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early recurrent cardiovascular events after acute myocardial infarction. Cholesterol efflux",
      "confidence": "medium"
    },
    {
      "pmid": "35524914",
      "title": "ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "The elevated adverse cardiovascular event rate among patients with low high-density lipoprotein cholesterol (HDL-C) formed the basis for the hypothesis that elevating HDL-C would reduce those events. ",
      "confidence": "medium"
    }
  ],
  "top_pmids": [
    "31567014",
    "18287885",
    "28069582",
    "25030535",
    "28939717",
    "25170076",
    "23072735",
    "26363436",
    "40263360",
    "17430166",
    "35120132",
    "37913855",
    "27630170",
    "16285990",
    "22986928",
    "40371638",
    "26681753",
    "31904503",
    "29437574",
    "35524914"
  ]
}